Roquefort Therapeutics plc announced appointment of Professor Sir Martin Evans will as a Non-Executive Director going forward and relinquish the role of Chief Scientific Officer. In addition, Dr. Michael Stein has completed his tenure as a Non-Executive Director and leaves the Board effective immediately. In due course, as programs progress into clinical trials, the Company will augment the Board and the Scientific Advisory Board with the requisite clinical development expertise.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.75 GBX | -1.04% | +7.95% | -34.48% |
05-23 | Windward wins deal; Kodal progresses at Bougouni | AN |
05-23 | Roquefort Therapeutics plc Announces Executive and Board Changes | CI |
1st Jan change | Capi. | |
---|---|---|
-34.48% | 7.75M | |
+1.34% | 94.38B | |
+26.70% | 67.18B | |
+7.06% | 64.45B | |
+15.06% | 44.79B | |
+12.47% | 42.43B | |
+26.64% | 37.37B | |
+7.08% | 25.75B | |
-4.47% | 22.29B | |
-0.28% | 18.39B |
- Stock Market
- Equities
- ROQ Stock
- News Roquefort Therapeutics plc
- Roquefort Therapeutics plc Announces Executive and Board Changes